CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM)

被引：0
|
作者：
Popat, Rakesh [1 ]
Wilson, William [2 ]
Camilleri, Marquita [2 ,3 ]
De Tute, Ruth
Pang, Gavin [2 ]
Jenner, Richard [2 ]
Dadaga, Tushhar [2 ]
Kamora, Sumaiya [2 ]
Streetly, Matthew [4 ]
Ramasamy, Karthik [5 ]
Phillips, Elizabeth [6 ]
Chapman, Mike [7 ]
Bygrave, Ceri [8 ]
Cavenagh, James [9 ]
Sive, Jonathan [2 ,10 ]
Benjamin, Reuben
Eccersley, Lydia [9 ]
Hassan, Sandra [11 ]
Willis, Fenella [12 ]
Clifton-Hadley, Laura [13 ]
Owen, Roger [14 ]
Yong, Kwee [2 ]
机构：
[1] Univ Coll London Hosp NHS Fdn Trust, London, England
[2] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England
[3] St James Hosp Leeds, HMDS, Leeds, W Yorkshire, England
[4] Guys & St Thomas NHS Trust, Leeds, W Yorkshire, England
[5] Univ Oxford, Hosp NHS Trust, Oxford, England
[6] Christie NHS Fdn Trust, Manchester, Lancs, England
[7] Cambridge Inst Med Res, Cambridge, England
[8] Univ Hosp Wales, London, England
[9] Barts Hlth NHS Trust, London, England
[10] Kings Coll Hosp London, London, England
[11] Queens Hosp, London, England
[12] St Georges NHS Trust, London, England
[13] UCL, Canc Res UK & UCL Canc Trials Ctr, London, England
[14] St James Inst Oncol, London, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-003
引用
收藏
页码：S2 / S3
页数：2
相关论文
共 50 条
  • [1] Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).
    Yong, Kwee
    Camilleri, Marquita
    Wilson, William
    Ramasamy, Karthink
    Streetly, Matthew J.
    Sive, Jonathan
    Bygrave, Ceri
    Chapman, Michael A.
    De Tute, Ruth
    Chavda, Selina J.
    Phillips, Elizabeth
    Cuadrado, Maria
    Pang, Gavin
    Jenner, Richard
    Dadaga, Tushhar
    Kamora, Sumaiya
    Cavenagh, James D.
    Clifton-Hadley, Laura
    Owen, Roger G.
    Popat, Rakesh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Upfront Autologous Stem Cell Transplantation (ASCT) Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Cardamon Study According to Cytogenetic Risk
    Yong, Kwee
    Wilson, William
    Camilleri, Marquita
    Ramasamy, Karthik
    Streetly, Matthew
    Sive, Jonathan
    Bygrave, Ceri A.
    Chapman, Michael
    de Tute, Ruth M.
    Chavda, Selina J.
    Phillips, Elizabeth H.
    Cuadrado, Maria del Mar
    Pang, Gavin
    Jenner, Richard
    Dadaga, Tushhar
    Kamora, Sumaiya
    Cavenagh, James
    Clifton-Hadley, Laura
    Owen, Roger G.
    Popat, Rakesh
    BLOOD, 2021, 138
  • [3] Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM)
    Gay, Francesca
    Cerrato, Chiara
    Scalabrini, Delia Rota
    Galli, Monica
    Belotti, Angelo
    Zamagni, Elena
    Ledda, Antonio
    Grasso, Mariella
    Angelucci, Emanuele
    Liberati, Anna Marina
    Tosi, Patrizia
    Pisani, Francesco
    Spada, Stefano
    Annibali, Ombretta
    Baraldi, Anna
    Omede, Paola
    Galieni, Piero
    Rizzi, Rita
    Pescosta, Norbert
    Ronconi, Sonia
    Vincelli, Donatella
    Cafro, Anna Maria
    Offidani, Massimo
    Palumbo, Antonio
    Musto, Pellegrino
    Cavo, Michele
    Boccadoro, Mario
    BLOOD, 2018, 132
  • [4] Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM).
    Gay, Francesca Maria
    Scalabrini, Delia Rota
    Belotti, Angelo
    Offidani, Massimo
    Petrucci, Maria Teresa
    Esma, Fabrizio
    Palmas, Angelo D.
    Caravita, Tommaso
    Grasso, Mariella
    Aquino, Sara
    Gamberi, Barbara
    Zambello, Renato
    Ledda, Antonio
    Montefusco, Vittorio
    Omede, Paola
    Galli, Monica
    Cavo, Michele
    Palumbo, Antonio
    Musto, Pellegrino
    Boccadoro, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients
    Palumbo, Antonio
    Bringhen, Sara
    Villani, Oreste
    Siniscalchi, Agostina
    Russo, Eleonora
    Uccello, Giuseppina
    Cerrato, Chiara
    Gilestro, Milena
    Rossi, Davide
    Boccadoro, Mario
    BLOOD, 2012, 120 (21)
  • [6] Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide- dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2 non-inferiority trial
    Yong, Kwee
    Wilson, William
    de Tute, Ruth M.
    Camilleri, Marquita
    Ramasamy, Karthik
    Streetly, Matthew
    Sive, Jonathan
    Bygrave, Ceri A.
    Benjamin, Reuben
    Chapman, Michael
    Chavda, Selina J.
    Phillips, Elizabeth H.
    del Mar Cuadrado, Maria
    Pang, Gavin
    Jenner, Richard
    Dadaga, Tushhar
    Kamora, Sumaiya
    Cavenagh, James
    Clifton-Hadley, Laura
    Owen, Roger G.
    Popat, Rakesh
    LANCET HAEMATOLOGY, 2023, 10 (02): : E93 - E106
  • [7] CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE VS CARFILZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE INDUCTION: PLANNED INTERIM ANALYSIS OF THE RANDOMIZED FORTE TRIAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Gay, F.
    Scalabrini, D. Rota
    Belotti, A.
    Offidani, M.
    Tacchetti, P.
    Petrucci, M. T.
    Pautasso, C.
    Palmas, A. D.
    Siniscalchi, A.
    Grasso, M.
    Spadano, A.
    Giuliani, N.
    Ballanti, S.
    Patriarca, F.
    Canepa, L.
    Bernardini, A.
    Aquino, S.
    Gamberi, B.
    Zambello, R.
    Ledda, A.
    Montefusco, V.
    Omede, P.
    Galli, M.
    Cavo, M.
    Palumbo, A.
    Musto, P.
    Boccadoro, M.
    HAEMATOLOGICA, 2017, 102 : 143 - 144
  • [8] Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma
    Forsberg, Peter A.
    Rossi, Adriana C.
    Boyer, Angelique
    Pearse, Roger N.
    Pekle, Karen A.
    Jayabalan, David
    Lakritz, Stephanie
    Flicker, Kari
    Ribadeneyra, Drew
    Liotta, Brielle
    Ely, Scott
    Boussi, Leora
    Allan, John N.
    Coleman, Morton
    Niesvizky, Ruben
    Mark, Tomer M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (12) : 1554 - 1562
  • [9] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
    Jasielec, Jagoda K.
    Kubicki, Tadeusz
    Raje, Noopur
    Vij, Ravi
    Reece, Donna
    Berdeja, Jesus
    Derman, Benjamin A.
    Rosenbaum, Cara A.
    Richardson, Paul
    Gurbuxani, Sandeep
    Major, Sarah
    Wolfe, Brittany
    Stefka, Andrew T.
    Stephens, Leonor
    Tinari, Kathryn M.
    Hycner, Tyler
    Rojek, Alexandra E.
    Dytfeld, Dominik
    Griffith, Kent A.
    Zimmerman, Todd M.
    Jakubowiak, Andrzej J.
    BLOOD, 2020, 136 (22) : 2513 - 2523
  • [10] WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Bringhen, S.
    De Paoli, L.
    Larocca, A.
    Ballanti, S.
    Gentilini, F.
    Liberati, A. M.
    Passera, R.
    Bernardini, A.
    Esma, F.
    Galieni, P.
    Offidani, M.
    Corradini, P.
    Gaidano, G.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 2 - 2
12345